OncLive TV

William P. Harris, MD, discusses the adoption of immunotherapy in advanced hepatocellular carcinoma.

Hans Lee, MD, discusses the evolving treatment paradigm in relapsed/refractory multiple myeloma.

Jeremy C. Jones, MD, discusses key lessons learned from the phase 3 KEYNOTE-177 trial.

Lyndsay Willmott, MD, discusses the importance of genetic testing in ovarian cancer.

Chris Labaki, MD, discusses racial disparities with regard to mammography screenings during the COVID-19 pandemic.

Quoc-Dien Trinh, MD, discusses findings from a study examining the temporal changes in cancer tests and diagnoses in a large healthcare system in the United States during the COVID-19 pandemic. 

Daniel C. Danila, MD, discusses the integration of advanced imaging in prostate cancer.

Suzanne Lentzsch, MD, discusses the utility of cellular therapies in multiple myeloma.

Joseph Mikhael, MD, discusses treatment selection for early relapse in multiple myeloma.

Su H. Wang, MD, MPH, discusses the rationale for the integration of viral hepatitis screening and care in a hospital system as the first steps for preventing liver cancers like hepatocellular carcinoma.

Kelly Garvin, MA, BSN, RN, discusses the impact of CAR T-cell therapy on the treatment of patients with non-Hodgkin lymphoma.

Chasity Washington, MPH, CHES, discusses strategies for addressing disparities in cancer care.

Nagla Abdel Karim, MD, discusses the rationale for the phase 3 CheckMate-73L trial that is being conducted in patients with stage III non–small cell lung cancer that is unable or not planned to be removed by surgery.

Michael J. Mauro, MD, discusses considerations for early treatment initiation in myelofibrosis.

Meghan Thompson, MD, discusses future research directions in chronic lymphocytic leukemia.

Jyoti Malhotra, MD, MPH, discusses the rationale to evaluate racial disparities in lung cancer survivors.

Anita Kumar, MD, discusses the improved efficacy of venetoclax when used in combination with ibrutinib compared with venetoclax or ibrutinib alone in mantle cell lymphoma. 

Stacey A. Cohen, MD, discusses the standardization of triplet-based chemotherapy regimens in colorectal cancer.

Mark D. Pegram, MD, discusses considerations for treatment selection in HER2-positive breast cancer.

Christopher Flowers, MD, discusses efforts to improve the frontline standard of care in diffuse large B-cell lymphoma.

Mustafa Özguröğlu, MD, discusses the individualization of treatment in non-small cell lung cancer.

Sonam Puri, MD, discusses recent research on clinically relevant biomarkers in small cell lung cancer. 

Elisabet E. Manasanch, MD, discusses key lessons learned from the phase 3 CASSIOPEIA trial in patients with newly diagnosed multiple myeloma.

Raajit K. Rampal, MD, PhD, discusses symptoms of disease progression in myelofibrosis.

Anita Kumar, MD, discusses patient factors to consider when selecting treatment in relapsed/refractory mantle cell lymphoma.

Jae H. Park, MD, discusses emerging CAR T-cell therapies in hematologic malignancies.

C. Ola Landgren, MD, PhD, discusses novel therapeutic approaches that are generating excitement in multiple myeloma.

Christine Sam, MD, shares strategies to manage interstitial lung disease experienced with fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer.

Gareth J. Morgan, MD, PhD, discusses differences in low- and high-risk multiple myeloma.

Tycel Jovelle Phillips, MD, discusses the future of CAR T-cell therapy in mantle cell lymphoma patients.